Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Dec;129(12):1344-1356.
doi: 10.1016/j.ophtha.2022.07.003. Epub 2022 Jul 12.

Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 5 Years of Follow-up

Steven J Gedde  1 , William J Feuer  2 , Kin Sheng Lim  3 , Keith Barton  4 , Saurabh Goyal  5 , Iqbal I Ahmed  6 , James D Brandt  7 ; Primary Tube Versus Trabeculectomy Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 5 Years of Follow-up

Steven J Gedde et al. Ophthalmology. 2022 Dec.

Abstract

Purpose: To report 5-year treatment outcomes in the Primary Tube Versus Trabeculectomy (PTVT) Study.

Design: Multicenter randomized clinical trial.

Participants: A total of 242 eyes of 242 patients with medically uncontrolled glaucoma and no previous incisional ocular surgery, including 125 patients in the tube group and 117 patients in the trabeculectomy group.

Methods: Patients were enrolled at 16 clinical centers and randomly assigned to treatment with a tube shunt (350-mm2 Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 2 minutes).

Main outcome measures: The primary outcome measure was the rate of surgical failure, defined as intraocular pressure (IOP) > 21 mmHg or reduced < 20% from baseline, IOP ≤ 5 mmHg, reoperation for glaucoma, or loss of light perception. Secondary outcome measures included IOP, glaucoma medical therapy, and visual acuity.

Results: The cumulative probability of failure after 5 years of follow-up was 42% in the tube group and 35% in the trabeculectomy group (P = 0.21; hazard ratio = 1.31; 95% confidence interval = 0.86-2.01). At 5 years, IOP (mean ± standard deviation) was 13.4 ± 3.5 mmHg in the tube group and 13.0 ± 5.2 mmHg in the trabeculectomy group (P = 0.52), and the number of glaucoma medications (mean ± standard deviation) was 2.2 ± 1.3 in the tube group and 1.3 ± 1.4 in the trabeculectomy group (P < 0.001).

Conclusions: Trabeculectomy with MMC and tube shunt surgery produced similar IOPs after 5 years of follow-up in the PTVT Study, but fewer glaucoma medications were required after trabeculectomy. No significant difference in the rate of surgical failure was observed between the 2 surgical procedures at 5 years.

Keywords: Glaucoma surgery; Randomized clinical trial; Trabeculectomy; Tube shunt.

PubMed Disclaimer

Conflict of interest statement

The other authors report no financial interest in the subject matter of this paper.

Figures

Figure 1.
Figure 1.
Flowchart of patient progress in the PTVT Study.
Figure 2.
Figure 2.
Kaplan-Meier plots showing the cumulative probability of failure in the PTVT Study. The number of patients at risk at each follow-up visit is shown at the bottom.
Figure 3.
Figure 3.
Kaplan-Meier plots showing the cumulative probability of failure in the PTVT Study defining inadequate intraocular pressure (IOP) reduction as IOP > 17 mmHg or reduced < 20% below baseline (A) or IOP > 14 mmHg (B). Inadequate IOP reduction criteria must have been present on 2 consecutive visits after 3 months to qualify as failure. Patients with persistent hypotony, reoperation for glaucoma, and loss of light perception vision are classified as failures. The number of patients at risk at each follow-up visit is shown at the bottom.
Figure 4.
Figure 4.
Kaplan-Meier plots showing the cumulative probability of failure in the PTVT Study among patients with preoperative intraocular pressure < 21 mmHg (A), 21–25 mmHg (B), and > 25 mmHg (C). The number of patients at risk at each follow-up visit is shown at the bottom.
Figure 5.
Figure 5.
IOP at baseline and follow-up in the PTVT Study. Data are presented as mean ± standard error of the mean. Patients were censored after a reoperation for glaucoma.
Figure 6.
Figure 6.
Scatter plot of IOP data in the PTVT Study. Each point represents a patient in the tube group (circle) or trabeculectomy group (diamond) showing the IOP at baseline and 5 years postoperatively. The oblique line indicates no change. Patients were censored after a reoperation for glaucoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429–440. - PubMed
    1. Vinod K, Gedde SJ, Feuer WJ, et al. Practice preferences for glaucoma surgery: A survey of the American Glaucoma Society. J Glaucoma 2017;26:687–693. - PMC - PubMed
    1. Gedde SJ, Chen PP, Heuer DK, et al. The Primary Tube Versus Trabeculectomy (PTVT) Study: Methodology of a multicenter randomized clinical trial comparing tube shunt surgery and trabeculectomy with mitomycin C. Ophthalmology 2018;125:774–781. - PMC - PubMed
    1. Gedde SJ, Feuer WJ, Shi W, et al. Treatment outcomes in the Primary Tube Versus Trabeculectomy Study after 1 year of follow-up. Ophthalmology 2018;125:650–663. - PubMed
    1. Gedde SJ, Feuer WJ, Lim KS, et al. Treatment outcomes in the Primary Tube Versus Trabeculectomy Study after 3 years of follow-up. Ophthalmology 2020;127:333–345. - PubMed

Publication types